Table 1.
Clinical characteristics of atrial fibrillation recurrence (AFR) and no recurrence (NR) groups at baseline
| Characteristic | Overall | AFR group | NR group | p value |
|---|---|---|---|---|
| N | 63 | 29 (46.0%) | 34 (54.0%) | |
| Age (years) | 63.1±9.9 | 65.0±8.7 | 61.6±10.7 | 0.178 |
| Female | 25 (39.7%) | 11 (37.9%) | 14 (41.2%) | 0.793 |
| AF: Paroxysmal | 47 (74.6%) | 18 (62%) | 29 (85.3%) | 0.688 |
| Persistent | 16 (25%) | 11 (38%) | 5 (14.7%) | 0.23 |
| Structural heart disease | 2 (3.2%) | 2 (6.9%) | 0 (0.0%) | 0.208 |
| Coronary artery disease | 7 (11.1%) | 3 (10.3%) | 4 (11.8%) | 1 |
| Congestive heart failure | 1 (1.6%) | 0 (0.0%) | 1 (2.9%) | 1 |
| CVA/TIA | 3 (4.7%) | 2 (6.9%) | 1 (2.9%) | 0.8 |
| Hypertension | 33 (53.2%) | 16 (57.1%) | 17 (50.0%) | 0.876 |
| Diabetes mellitus | 9 (14.3%) | 4 (13.8%) | 5 (14.7%) | 1 |
| Hyperlipidemia | 35 (55.6%) | 20 (69.0%) | 15 (44.1%) | 0.048 |
| Obesity | 8 (12.7%) | 5 (17.2%) | 3 (8.8%) | 0.317 |
| Obstructive sleep apnea | 18 (28.6%) | 11 (37.9%) | 7 (20.6%) | 0.129 |
| Coumadin | 43 (68.3%) | 23 (79.3%) | 20 (58.8%) | 0.082 |
| Aspirin | 27 (42.9%) | 13 (44.8%) | 14 (41.2%) | 0.77 |
| Statins | 25 (39.7%) | 14 (48.3%) | 11 (32.4%) | 0.198 |
| Ca channel blockers | 21 (33.9%) | 9 (31.0%) | 12 (36.4%) | 0.658 |
| Beta-blockers | 49 (77.8%) | 26 (89.7%) | 23 (67.7%) | 0.036 |
| Anti-arrhythmic agents | 61 (97%) | 29 (100%) | 32 (94%) | 0.2 |
| Ablation procedure | ||||
| PVI | 44 (70%) | 20 (69%) | 24 (70.5%) | 0.68 |
| WACA | 19 (30%) | 9 (31%) | 10 (29.5%) | 0.68 |